To learn more about our products please choose a therapeutic area and download the Summary of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs). This information is intended only for UK residents.
Arlevert (cinnarizine 20mg, dimenhydrinate 40mg) was developed by Hennig Arzneimittel GmbH & Co of Germany. Hampton has exclusive rights to Arlevert in the UK where it is indicated for the treatment of vertigo symptoms of various origins.
|Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also be reported to Hampton Pharmaceuticals on email@example.com or 01923 204322|